Tovilla-Canales JL, Varón-Munar D, Pedroza SM

Idioma: Español
Referencias bibliográficas: 17
Paginas: 33-38
Archivo PDF: 196.23 Kb.

FRAGMENTO

La inflamación ocular es uno de los principales problemas en la consulta oftalmológica. El tratamiento puede ser específico (tratando directamente la causa) o bien inespecífico (reduciendo los síntomas inflamatorios). La piedra angular del tratamiento de la gran mayoría de las inflamaciones inespecíficas oculares son los corticoesteroides, sin embargo, las complicaciones asociadas a éstos ha planteado la posibilidad de utilizar fármacos alternos que permitan lograr resultados similares con menos reacciones adversas como los antiinflamatorios no esteroideos (AINEs).

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bishop K, Abelson M, Cheetham J et al. Evaluation of flurbiprofen in the treatment of antigen-induced allergic conjunctivitis. Invest Ophthalmol Vis Sci. 1989; 31: 487.

2. Shelvin HH. The pharmacology of the nonsteroidal agents. In: Solomon LD. ed Proceedings of the Opthalmic NSAID Roundtable. Medicopea 2nd ed. 1992: 17-24.

3. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42: 807-810.

4. Fleisher LN. Effects of inhibitors of arachidonic acid metabolism on endotoxin-induced ocular inflammation. Curr Eye Res 1988; 7(3): 321-327.

5. Chiou LY, Chiou GCY. Ocular antiinflammatory action of a lipo-oxigenase inhibitor in the rabbit. J Ocul Pharmacol 1985; 1: 383.

6. Cervantes-Coste G, Sanchez-Castro Y, Orozco Carroll M et al. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology 2009; 3: 219-226.

7. Lane S, Modi S, Lehmann R, Hollan EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33: 53-58

8. Hariprasad S, Callanan D. Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema. Retinal cases & brief reports 2007; 10: 1-6.

9. O’Brien TP. Emerging guidelines for use of NSAID to optimize cataract surgery patient care. Curr Medical Research and Opinion 2005; 21: 1131-1137.

10. Giordano M. Long-term prophylaxis of recurring spondylitic iridocyclitis with antimalarials and non-steroidal antiphlogistics. Z Rheumatol 1982; 41: 105-106.

11. Olsen NY, Lindsley CB, Godfrey WA. Nonsteroidal antiinflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Chile 1998; 142: 1289-1292.

12. Friedlaender MH, Jackson BW, Abelson MB, Tinkelman DG, Ballas Z. Allergic Conjunctivitis. Survey of Ophthalmology 1993, 38: Suppl: 105-114.

13. Tsai RJ, Sun TT, Tseng S. Comparison of limbal and conjunctival autograft transplantation in corneal surface reconstruction in rabbits. Ophthalmology 1990; 97: 446-455.

14. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal antiinflammatory drugs. Ophthalmology 2001; 108: 936-944.

15. Tovilla-Canales JL, Nava CA, Tovilla PJ. Orbital infections. Curr Opin Ophthalmol 2001; 12: 335-341.

16. Smith AT, Spencer JT. Orbital complications resulting from lesions of the sinuses. Ann Otol Rhinol Laryngol 1948; 57: 514.

17. Shuttleworth G, Harrad R. Management of acute eyelid conditions. The Practitioner 2000; 244: 138-143.